🇺🇸 FDA

Company profile · Sponsor

Stoke

Stoke Therapeutics

STOK · NYSE pharma BEDFORD, MA, USA
Pipeline
8
Drugs
0
Patents
8

Quick answer

Stoke (STOK) is a pharma company. headquartered in BEDFORD, MA, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker STOK
Exchange NYSE
Company type pharma
Headquarters BEDFORD, MA, USA
SEC CIK 0001623526

Pipeline (8)

Search pipeline →

  1. STK-001, STK-001

    Stoke

    Dravet syndrome

    phase 3 small molecule active

    1 trial

  2. zorevunersen

    Stoke

    Dravet Syndrome

    phase 3 small molecule active

    1 trial

  3. Milrinone

    Stoke

    Valvular Stenosis

    phase 2 small molecule completed

    1 trial

  4. STK-001 - Single Ascending Doses

    Stoke

    Dravet Syndrome

    phase 2 small molecule completed

    1 trial

  5. zorevunersen (STK-001)

    Stoke

    Dravet Syndrome

    phase 2 small molecule active

    1 trial

  6. STK-002

    Stoke

    Autosomal Dominant Optic Atrophy

    phase 1 small molecule active

    1 trial

  7. Pethidine

    Stoke

    Pain Relief in Labour

    approved small molecule completed

    1 trial

  8. Transanal irrigation with Peristeen Anal Irrigation

    Stoke

    Constipation

    approved other completed

    1 trial

Patents (8)

Search patents →

  1. US 12338437

    OPA1 antisense oligomers for treatment of conditions and diseases

    Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12060558

    Methods and compositions for treatment of cholesteryl ester storage disease

    Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11873490

    Antisense oligomers for treatment of conditions and diseases

    Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11814622

    OPA1 antisense oligomers for treatment of conditions and diseases

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11096956

    Antisense oligomers and uses thereof

    Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11083745

    Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome

    Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10913947

    Antisense oligomers for treatment of conditions and diseases

    Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10683503

    Antisense oligomers for treatment of conditions and diseases

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Stoke?

Stoke (STOK) is a pharma company. headquartered in BEDFORD, MA, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Stoke sponsor?

We track 8 ClinicalTrials.gov-linked programs for Stoke, including STK-001, STK-001 and 7 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Stoke company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.